Investment
Features
FeesSafety
Academy
More
Pluang+

Co-Diagnostics ships mosquito surveillance tech to overseas USAF base, marking first international expansion.

Market News
01 Sep 2026
PRNewsWire
View Source
Bullish
pluang ai news

Co-Diagnostics has made its first international shipment of Vector Smart mosquito surveillance equipment to a United States Air Force base overseas. This expansion follows domestic growth, where the platform serves 40 customers across 21 U.S. states. Vector Smart uses multiplex PCR assays to detect mosquito-borne pathogens like West Nile virus and Zika, aiding public health efforts. The company aims to grow its presence in government, military, and public health markets, positioning Vector Smart as a key part of its long-term strategy.

More News

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...

Company Fundamentals
Bullish
1 hour ago
Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...

Company Fundamentals
Bullish
1 hour ago
Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...

Analyst Insights
Bullish
2 hours ago
SAIC raises price target after beating Q2 earnings and boosting 2027 outlook

SAIC raises price target after beating Q2 earnings and boosting 2027 outlook

Science Applications International Corporation (SAIC) saw its price target raised to $154 after reporting Q2 earnings of $3.01 per share, surpassing estimates by over 33%, and revenues of $1.88 billion, beating expectations by 7.52%. The company also...

Analyst Insights
Bullish
3 hours ago
Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

UBS upgraded Hercules Capital's rating from Neutral to Buy, reflecting confidence in the company's strong financial stability and growth prospects. Hercules Capital, a specialty finance firm supporting tech and life sciences startups, boasts a BBB+ c...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App